Figure 1.
Figure 1. Clinical response to pegylated l-asparaginase (PEG-Asp) in pediatric acute lymphoblastic leukemia (ALL). Clinical response to 1000 IU/m2 intravenous PEG-Asp, measured as the decrease in the absolute number of leukemic cells in the peripheral blood of 31 children with ALL. The final values at day 0 are shown for each individual by dots. The clinical response line shows the median and 25th and 75th percentiles. A good clinical response is defined by less than 1 × 109/blasts/L at day 0, an intermediate response by 1 × 109/blasts/L to 10 × 109/blasts/L on day 0, and poor response by more than 10 × 109/blasts/L at day 0. Dotted lines indicate the cut-off values for these clinical responses.

Clinical response to pegylated l-asparaginase (PEG-Asp) in pediatric acute lymphoblastic leukemia (ALL). Clinical response to 1000 IU/m2 intravenous PEG-Asp, measured as the decrease in the absolute number of leukemic cells in the peripheral blood of 31 children with ALL. The final values at day 0 are shown for each individual by dots. The clinical response line shows the median and 25th and 75th percentiles. A good clinical response is defined by less than 1 × 109/blasts/L at day 0, an intermediate response by 1 × 109/blasts/L to 10 × 109/blasts/L on day 0, and poor response by more than 10 × 109/blasts/L at day 0. Dotted lines indicate the cut-off values for these clinical responses.

Close Modal

or Create an Account

Close Modal
Close Modal